BCR-ABL translocations had previously been shown to have poor outcomes in MPAL, but with the addition of TKI therapy to an ALL backbone they have outcomes similar to Ph+ B-ALL [65]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.